Ataxia Drug Cost Must Fall for HSE Purchase, Says NCPE

A drug intended to treat Friedreich's Ataxia requires a substantial price cut before the Health Service Executive (HSE) will consider its purchase, according to the National Centre for Pharmacoeconomics (NCPE).

The NCPE's assessment indicates that the current cost of the medication is prohibitively high, presenting a significant obstacle to its adoption within the Irish healthcare system. This recommendation directly affects individuals living with Friedreich's Ataxia, a rare genetic disorder that affects the nervous system, by limiting their access to potentially life-changing treatments.

The NCPE's role is to evaluate the cost-effectiveness of new drugs to ensure that public funds are used responsibly. Their decision underscores the ongoing challenge of balancing the introduction of innovative but expensive medical therapies with the need for affordable healthcare for all.

“

There would have to be "significant price reduction" in the cost of a drug to treat Friedreich's Ataxia for it to be covered by the HSE according to the National Centre for Pharmacoeconomics (NCPE).